BioCardia to Host 2024 Financial Results and Corporate Update Conference Call on March 31, 2025

Rhea-AI Summary

BioCardia (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases, has scheduled key events for March 2025. The company will release its 2024 financial results on March 26, 2025, followed by a corporate update conference call on March 31, 2025.

Additionally, BioCardia will present the principal results of the CardiAMP-HF Trial at the American College of Cardiology 2025 Scientific Sessions in Chicago on March 30, 2025. The presentation will focus on 'A Double-blind, Randomized Controlled Trial of an Autologous Cell Therapy in Patients with HFrEF'.

SUNNYVALE, Calif., March 21, 2025 (GLOBE NEWSWIRE) -- BioCardia^®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will report its financial results for the year ended December 31, 2024 on Wednesday, March 26, 2025, and will host a corporate update conference call on Monday, March 31, 2025 (time and dial-information to be announced). The conference call will follow the presentation, “A Double-blind, Randomized Controlled Trial of an Autologous Cell Therapy in Patients with HFrEF: Principal Results from the CardiAMP-HF Trial,” at the American College of Cardiology 2025 Scientific Sessions in Chicago on March 30, 2025.

About BioCardia^®
BioCardia, Inc., headquartered in Sunnyvale, California, is a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease. CardiAMP^® autologous and CardiALLO™ allogeneic cell therapies are the Company’s biotherapeutic platforms with three cardiac clinical stage product candidates in development. These therapies are enabled by its Helix™ biotherapeutic delivery and Morph^® vascular navigation product platforms. For more information visit www.biocardia.com.

MEDIA CONTACT:
Miranda Peto, Investor Relations
mpeto@biocardia.com
(650) 226-0120

INVESTOR CONTACT:
David McClung, Chief Financial Officer
investors@biocardia.com
(650) 226-0120

FAQ

When will BioCardia (BCDA) release its 2024 financial results?

BioCardia will release its 2024 financial results on March 26, 2025.

What clinical trial results will BCDA present at ACC 2025?

BCDA will present the principal results from the CardiAMP-HF Trial, a double-blind, randomized controlled trial of autologous cell therapy in HFrEF patients.

When is BioCardia's (BCDA) corporate update conference call scheduled?

The corporate update conference call is scheduled for March 31, 2025, with time and dial-in details to be announced.

Where will BCDA present its CardiAMP-HF Trial results?

The results will be presented at the American College of Cardiology 2025 Scientific Sessions in Chicago on March 30, 2025.